Non-surgical treatment for Lung Cancer Flashcards

1
Q

What is the most common malignancy and leading cause of cancer-related mortality

A

Lung Cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Investigations of Lung Cancer (3)

A

CXR
CT
Bronchoscopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Histological Sub-types (2)

A

NSCLC- non small cell lung cancer

SCLC- Small cell lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

NSCLC (3)

A

Squamous
Adenocarcinoma
Large cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Other histological subtypes of lung cancer (4)

A

Pleural mesothelioma
Epitheloid
Sarcomatous
Biphasic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Doubling time of Non-small Cell Lung Cancer

A

129 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the maximum operable/resectable of NSCLC

A

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tests used for staging

A

PET

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Purpose of MDT

A

Discuss results and therapeutic options

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Options for treatment (5)

A
Surgery
Radiotherapy
Chemotherapy
Targeted therapies
Supportive care only
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Stages in Eastern Cooperative Group Performance Status Measurement

A

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

1 (ECOG)

A

asymptomatic; well

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

2 (ECOG)

A

Symptomatic, able to do light work

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

3 (ECOG)

A

Has to rest for >50% of the day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

4 (ECOG)

A

Bed bound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

5 (ECOG)

17
Q

What are the 3 essential information to determine optimal therapy

A

Pathology
Stage
Performance status

18
Q

Treatment options for NSCLC

A

Surgery

Adjuvant Therapy

19
Q

For NSCLC when is it good and detrimental to give adjuvant

A

Good- Stage IB and II- cisplatin

Detrimental- mediastinal N2 nodes

20
Q

What trial proved the effectiveness of Durvlumab after CRT

A

PACIFIC Trial

21
Q

Dose of radical RT for Stage III NSCLC

22
Q

Number of fractions in Radical RT for stage III NSCLC

23
Q

What is essential before starting radical RT

A

Pulmonary Function Test

24
Q

What type of treatment is ChemoRT

25
What is SABR
Stereotactic Ablative radiotherapy
26
Dose of SABR (2)
54Gy in 3 fractions | High dose
27
When is SABR suitable
Useful if not fit for surgery Tumours up to 4-5 cm >2cm awat from airways and proximal bronchial tree
28
Treatment decisions in NSCLC are also affected by
Co-morbidity (angina, COPD)
29
Features of Stage IV NSCLC
Incurable Palliation is essential RT- symptom benefit Chemo- symptomatic and survival
30
What should be measured during NSCLC stage III and IV (3)
Quality of life: Painful bone metastases (RT single fraction) Brain metastases 9resection, RT, steroids, erlotinib)
31
Features of Bone pain from metastases (3)
Worse at night Pathological fracture Palliative RT
32
New developments in NSCLC (2)
Targeted drugs for adenocarcinoma (ALF, ROS, BRAF, EGFr) | Immunotherapy
33
Examples of Tyrosine Kinase Inhibitors
Erlotinib, Geftinib, Afatinib
34
Mechanism of Nivolumab
Blocks the binding of PD-1 (T ecll) to PDL-1 and PDL2 (tumour cell)
35
Preentation of small cell lung cancer is identical to
secretory syndromes SIADH, cushings
36
Treatment for SCLC (4)
Chemo Combination of drugs (Cisplatin + etopside) Early thoracic RT Prophylactic cranial radiation
37
2 types of SCLC
Limited and extensive
38
features of possible lung cancer screening (2)programme
At risk population | Low dose CT